182201-77-0

Basic information

• Product Name: S-((9H-fluoren-9-yl)methyl)-N-((allyloxy)carbonyl)-L-cysteine
• Synonyms: S-((9H-fluoren-9-yl)methyl)-N-((allyloxy)carbonyl)-L-cysteine;N-[(Allyloxy)carbonyl]-S-(9H-fluoren-9-ylmethyl)-L-cysteine;Alloc-Cys(Fm)-OH
• CAS NO: 182201-77-0
• Molecular Formula: C21H21NO4S
• Molecular Weight: 383.46074
• Mol File: 182201-77-0.mol
• Article Data: 0

Chemical Properties

• Boiling Point: 607.4±55.0 °C(Predicted)
• Appearance: /
• Density: 1.272±0.06 g/cm3(Predicted)
• PKA: 3.50±0.10(Predicted)
• CAS DataBase Reference: S-((9H-fluoren-9-yl)methyl)-N-((allyloxy)carbonyl)-L-cysteine(CAS DataBase Reference)
• NIST Chemistry Reference: S-((9H-fluoren-9-yl)methyl)-N-((allyloxy)carbonyl)-L-cysteine(182201-77-0)
• EPA Substance Registry System: S-((9H-fluoren-9-yl)methyl)-N-((allyloxy)carbonyl)-L-cysteine(182201-77-0)

Safety Data

• Hazardous Substances Data: 182201-77-0(Hazardous Substances Data)

Usage

Description

S-((9H-fluoren-9-yl)methyl)-N-((allyloxy)carbonyl)-L-cysteine is a complex organic compound that serves as a crucial intermediate in the synthesis of pharmaceuticals. It is characterized by its unique molecular structure, which includes a 9H-fluoren-9-ylmethyl group attached to the sulfur atom of L-cysteine, and an allyloxycarbonyl group attached to the nitrogen atom. S-((9H-fluoren-9-yl)methyl)-N-((allyloxy)carbonyl)-L-cysteine plays a significant role in the development of potent antitumor agents, making it a valuable component in the field of medicinal chemistry.

Uses

Used in Pharmaceutical Industry:
S-((9H-fluoren-9-yl)methyl)-N-((allyloxy)carbonyl)-L-cysteine is used as a key reactant in the synthesis of Ecteinascidin 743, also known as Trabectedin. Trabectedin is a potent antitumor chemotherapy drug that has shown significant efficacy in the treatment of various types of cancer, including soft tissue sarcoma and ovarian cancer. S-((9H-fluoren-9-yl)methyl)-N-((allyloxy)carbonyl)-L-cysteine's unique structure allows for the formation of a complex molecular framework that contributes to Trabectedin's therapeutic properties.
In the synthesis process, S-((9H-fluoren-9-yl)methyl)-N-((allyloxy)carbonyl)-L-cysteine undergoes a series of chemical reactions to form the final drug product. Its presence is essential for the successful production of Trabectedin, highlighting its importance in the pharmaceutical industry.
Furthermore, the development of S-((9H-fluoren-9-yl)methyl)-N-((allyloxy)carbonyl)-L-cysteine as a reactant for the synthesis of Trabectedin has opened up new avenues for research in the field of medicinal chemistry. Scientists are continually exploring ways to improve the synthesis process, enhance the drug's efficacy, and reduce its side effects, making this compound a vital component in the ongoing quest for better cancer treatments.